WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Review of Stability Indicating Methods and Forced Degradation Studies

Jayshree Kishor Sonawane[1]*, Siddhi Maruti Chavan[2], Ishwari Prakash Narkar[3], Snehal Chandrashekhar Jale[4], Nidhee Vinayak Tendulkar[5], Prof. Vaishali Jadhav[6], Dr. Ashish Jain[7].

[1,2,3,4,5,6,7]Department of Quality Assurance, Shri. D.D. Vispute College of Pharmacy and Research Center, Devad-Vichumbe, Panvel - 410221, Maharashtra, India.

E-mail: jayshreesonawane1444@gmail.com

DOI- https://doi.org/10.55248/gengpi.4.523.42372

ABSTRACT:

Stability testing of pharmaceutical products is a complex collection of processes requiring significant expense, time consumption, and scientific skill. In order to improve the quality, efficacy, and safety of a pharmaceutical product, stability testing of drug substances and products is an important step in determining the best storage options and recommending labeling guidelines. The forced degradation parameter performed under stability testing is Hydrolytic degradation, Oxidation degradation, Acidic degradation, Alkaline degradation, and Thermal degradation. In this paper, we present a comprehensive review of the current state of the art of Conventional Techniques and Hyphenated Techniques in the analysis of drug degradation products. We also provide an overview of recent advances in high-performance liquid chromatography (HPLC) and Method development of pharmaceutical drugs.

Keywords: Stability study, Force degradation, Stress conditions for degradation, Regulatory guidelines for stability testing, Method development and validation.

1. Introduction:

In order to improve the quality, efficacy, and safety of a medication formulation, stability testing of pharmaceutical goods is a complex collection of processes requiring significant expense, time consumption, and scientific skill. The pharmaceutical analysis and stability tests that are necessary to ascertain and ensure the identity, potency, and purity of ingredients as well as those of the formed products are among the most crucial tasks during the developmental stages. The capacity of a specific formulation in a particular container/closure system to maintain its physical, chemical, microbiological, toxicological, protective, and informational characteristics is referred to as a pharmaceutical product's stability [(1)].

Thus, stability testing assesses how the environment affects a drug substance's or a manufactured product's quality in order to anticipate how long it will last, identify the best storage options, and recommend labeling guidelines. These elements include the active ingredient(s)' stability, interactions between the active ingredient(s) and excipients, manufacturing procedures used, dosage form type, packaging container/closure system, and environmental conditions for light, heat, and moisture encountered during transportation, storage, and handling [(2)]. Additionally, factors like reactant concentration, pH, radiation, catalysts, raw material usage, and the interval between production and use of the product all affect the stability of degradation reactions like oxidation, reduction, hydrolysis, or racemization, which can be extremely important for pharmaceutical products. A pharmaceutical product's stability may be impacted by changes to its appearance, consistency, content uniformity, clarity (solution), moisture content, particle size, shape, pH, and package integrity. These physical alterations may be brought on by impact, vibration, abrasion, and temperature changes like freezing, thawing, or shearing, among other things. Pharmaceutical products may become degraded as a result of chemical processes like solvolysis, oxidation, reduction, racemization, etc. These processes can also cause active pharmaceutical ingredients (API) to lose some of their potency and excipient activity, such as antioxidant and antimicrobial preservative activity [(3)].

2. International and Regulatory Guidelines for Stability Testing:

I. ICH Guidelines

II. FDA (Food and Drug Administration)

III. WHO (World Health Organization)

IV. USP (US Pharmacopoeia)

V. EMA (European Medical Association)

VI. ASEAN Guidelines.

Guideline	Title
Q1A(R2)	Stability testing of new drug substances and products
Q1B	Stability testing: photostability testing of new drug substances and products
Q1C	Stability testing for new dosage forms.
Q1D	Bracketing and matrixing designs for stability testing of new drug substances and products
Q1E	Evaluation of stability data
Q1F	Stability data package for registration applications in climatic zones iii and iv.
Q5C	Quality of biotechnological products: stability testing of Biotechnological/ biological products
Q2B	Validation of Analytical Procedure: Methodology
Q3A(R2)	Impurities in new drug product

3. Objective, Need, and Purpose of Stability Studies:

i. To identify the processes by which drug compounds and drug products degrade.

ii. To distinguish degradation products that are produced from the non-drug product in a formulation from those that are related to drug products.

iii. To ascertain a pharmacological substance's intrinsic stability inside the formulation.

iv. To identify the drug substance's and drug product's degradation processes, such as hydrolysis, oxidation, thermolysis, or photolysis

v. To produce a deterioration profile resembling what would be seen in an official stability study carried out under ICH guidelines.

vi. To create formulas that are more stable. It also aids in figuring out when a specific formulation will expire.

vii. Purpose is mentioned in Fig 1.

Essential for a new drug molecule	Unknown Degradation products, Known/unknown impurities structurally related by-products, and intermediates [4].
Essential for new dosage forms	Instability of API incompatibility with other actives and inactive [5,6]



Fig 1. Purpose of Degradation Studies

4. Types of Stability Studies:

I. Long-Term Stability

II. Intermediate Stability

III. Accelerated Stability

I. Long-Term Stability:

- Studies on stability under recommended storage conditions during the specified shelf life or retest period.
- This entails keeping the medication in cabinets or spaces with controlled temperatures under the worst-case scenarios for temperature and humidity.
- Over a minimum of 12 months, samples are analyzed after being periodically removed.
- Any process should be created to guarantee that the product maintains an acceptable level of quality for the duration of its suggested shelf life under the suggested storage conditions at the time it is marked.

II. Intermediate Stability:

- Research done at 30^0C/65% RH to somewhat speed up the rate of chemical deterioration or physical alterations for a drug substance or drug product intended for long-term use at 25^0C
- Studies were carried out in the event that accelerated studies failed and the temperature and humidity were between long-term and accelerated.

III. Accelerated Stability:

- Studies intended to accelerate the physical or chemical deterioration of active pharmaceutical products, medical equipment, or pharmaceutical products (i.e., drug products) by the use of inflated storage conditions as a part of the formally established storage program.
- By speeding the pace of decomposition, preferably by raising the reaction's temperature, a stability study can be used to estimate a product's shelf life.
- These are experimental designs.
- A pharmaceutical preparation's capacity to maintain its potency in a certain container closure mechanism is referred to as stability.
- The drug's concentration is expected to drop to 90% of its initial level by the end of its shelf life.
- Factors affecting the Shelf life of Drugs:

a. Moisture, Hydrolysis, and pH

b. Oxygen

c. Light

d. Temperature

e. Microbes

f. APIs and excipients

g. Physiological properties like hygroscopic nature, crystalline, or amorphous nature.

5. Types of Methods of SIAMs:

Titrimetric	Non-aqueous titration, Oxidation-Reduction, Iodometric assay	Amine, Sulphonamide, etc. Ferric ions B-lactam antibiotics

UV-VIS Spectrophotometry	Spectral selectivity can be increased by the use of different spectrophotometry and dual wavelength spectrophotometry	Dicloxacillin and Ampicillin, etc [6]
Chromatographic (TLC)	Used especially during initial stress testing to study the number of degradation products formed Limitation: variability, non-quantitative.	Cephalosporins [7].
HPTLC	Reliable, fast, and accurate for quantitative drug analysis, and many samples can be run simultaneously using a small quantity of mobile phase	Oxyphenbutazone [8]
GC	Is not very Versatile, as the drug substance may be non-volatile or thermally unstable	Impurities of ampicillin sodium, etc [10]
HPLC	High-resolution capacity, Sensitive, and Specificity, non-volatile, thermally unstable, or polar/ionic compounds.	Atenolol, Danazol, Nifedipine, Piroxicam, Captopril, Trimethoprim, Locasamide. [9]

6. Limits for degradation

There have been a lot of disagreements among pharmaceutical industry specialists on how much decomposition is required. Drug ingredient degradation between 5% and 20% have been recognized as suitable for the purpose of validating chromatographic tests. Some pharmaceutical scientists think 10% degradation is excellent for use in analytical validation for small pharmaceutical molecules, whose acceptable stability limits are typically 90% of the label claim.

A degradation product is not always produced through forced deterioration. The investigation may be concluded if no degradation is seen after exposure to stress conditions other than those specified in an accelerated stability protocol [11]. This illustrates the chemical's stability, which is being examined. Overstressing a sample could result in the creation of a secondary degradation product that would not be identified in formal shelf-life stability experiments while under-stressing a sample could result in insufficient degradation products [12]. The techniques for creating product-related degradation for drug substances and drug products may differ due to variations in matrices and concentrations. For method development, it is suggested that stressed samples be kept in solution for a maximum of 14 days (or, for oxidative tests, for a maximum of 24 hours). [13]

7. Strategy for selection of degradation conditions:

Forced degradation is used to provide representative samples for the development of stability-indicating protocols for medicinal components and therapeutic products. The stress parameters picked should be compatible with the product's decomposition under typical manufacture, storage, and user settings, which are described in each scenario. A typical protocol for drug substance and drug product degradation conditions is shown in Scheme 1.

The minimum list of stress elements advised for forced degradation studies includes acid and base hydrolysis, heat degradation, photolysis, and oxidation, whereas shear [14] and freeze-thaw cycles are optional as shown in Fig no 2. The regulatory standards make no mention of the pH, temperature, or specific oxidizing agents to be utilized. The design of photolysis studies is left to the applicant's discretion, even though Q1B specifies that the light source should produce combined visible and ultraviolet (UV, 320–400 nm) outputs and that exposure levels should be justified. The purpose of the initial study should be to determine what factors diminish the drug's effectiveness by around 10%. Some of the situations that are typically used for forced degradation investigations are listed in Table 1.



Fig 2. Force Degradation Study.

Scheme 1. Flowchart describing various stress conditions used for degradation of Drug Substance and Drug Product

Degradation type	Experimental conditions	Storage conditions	Sampling Time(days)
Hydrolysis	Control (no acid or base) 0.1 M Sodium Hydroxide 0.1 M Hydrochloric Acid Acid control (no API) Base Control (no API) pH: 2,4,6,8.	40^0C, 60^0C 40^0C, 60^0C 40^0C, 60^0C 40^0C, 60^0C 40^0C, 60^0C 40^0C, 60^0C	1,3,5 1,3,5 1,3,5 1,3,5 1,3,5 1,3,5
Oxidation	3% H2O2 Peroxide control Azobisisobutyronitrile (AIBN) AIBN control	25^0C, 60^0C 25^0C, 60^0C 40^0C, 60^0C 40^0C, 60^0C	1,3,5 1,3,5 1,3,5 1,3,5
Photolytic	Light 1 ICH Light 3 ICH Light control	Not Applicable Not Applicable Not Applicable	1,3,5 1,3,5 1,3,5
Thermal	Heat chamber Heat chamber Heat chamber Heat chamber Heat control	60^0C 60^0C/75%RH 80^0C 80^0C/75%RH Room Temperature	1,3,5 1,3,5 1,3,5 1,3,5 1,3,5[15]

Table 1. Conditions mostly used for forced degradation studies

8. Degradation Conditions:

i. Hydrolytic degradation:

A substance is degraded via the chemical process of hydrolysis known as neutral degradation when it interacts with water. The process is given in Fig 3.



Fig 3. Hydrolytic Degradation

Hydrolytic investigations in acidic and basic environments result in catalysis of the molecule's ionizable functional groups. Testing a pharmaceutical material under acidic or basic circumstances in order to force disintegration that produces principal degradants at an ideal level is known as acid or base stress testing. Depending on how stable the drug material is, different types and concentrations of bases or acids should be used. Hydrochloric acid or sulfuric acid (0.1-1 M) are suggested as acceptable reagents for acid hydrolysis, whereas sodium hydroxide or potassium hydroxide (0.1-1 M) are suggested for base hydrolysis as shown in Fig 4. [16]



Fig 4. Acid-Base Degradation

ii. Oxidative degradation:

Autoxidation, or oxidation under normal storage circumstances, occurs in many chemical compounds and uses ground-state elemental oxygen. As a result, it is an important pathway for the breakdown of numerous drugs. The free radical reaction known as autoxidation requires a free radical initiator to take place. Autoxidation may be started by hydrogen peroxide, metal ions, or trace impurities in a pharmacological drug. [17]

The sort of oxidizing agent to use, along with its concentration and environmental exposures, are determined by the pharmacological substance. According to some theories, exposing the solutions to 0.1–3% hydrogen peroxide at neutral pH for seven days could provide useful degradation products, up to a maximum of 20% degradation as given in Fig 5. [18]



Fig 5. Oxidation Degradation.

iii. Photolytic degradation:

To enable direct comparisons between the drug substance and drug product, samples should be exposed to light that provides an overall illumination of not less than 1.2 million lux hours and an integrated near ultraviolet energy of not less than 200-watt hours/square meter with a spectral distribution of 320-400nm. To verify that the desired light exposure is produced, samples may be exposed side by side using a validated chemical actinometric system, for the proper period of time when circumstances have been monitored with calibrated radiometers/lux meters, or both. By oxidizing functional groups with labile hydrogens, such as benzylic, carbon, allylic, and tertiary carbon, one can form hydroperoxides, hydroxides, and ketones. Both oxidative and nonoxidative photolytic mechanisms can lead to photolytic breakdown as shown in Fig 6. [19]



Fig 6. Photo Degradation

iv. Thermal condition:

Testing for thermal degradation (such as dry heat and wet heat) should not be done under the accelerated ICH Q1A testing settings that are indicated. Solid-state drug ingredients and drug products should be exposed to samples of both dry and moist heat. Liquid drug items should be heated to a dry temperature. Studies could be conducted for a shorter period of time at higher temperatures. To determine whether the temperature has an impact on a substance's capacity to withstand heat, the Arrhenius equation can be utilized. The rate of a particular reaction is denoted by the letter k, where A stands for the frequency factor, Ea for the energy of activation, R for the gas constant (1.987 cal/deg mol), and T for the absolute temperature. Thermal degradation investigations are carried out between 40 and 80^0 C. [20]

Humidity: 90% humidity for a week will normally be advised for the establishment of forced deterioration samples. Potential degradation products that may or may not arise under appropriate storage circumstances are produced by forced degradation experiments, but they aid in the development of stability-indicating methods. Any forced degradation strategy's goal is to achieve the desired level of degradation, between 5% and 20%. [21]

9. Stability indicating method

The active pharmaceutical ingredient (API) in drug products degrades over time, and the stability indicating method (SIM) is an analytical technique used to quantify this degradation. A stability-indicating method is a validated quantitative analytical procedure that can be used to determine how the stability of drug substances and drug products changes over time, according to an FDA guideline document [22]. Without interference from other degradation products, contaminants, or excipients, a stability-indicating method correctly gauges variations in active component concentration. [23] . Stress tests are conducted to show the developed method's specificity in measuring changes in drug substance concentration when knowledge of probable degradation products is limited. The pre-formulation studies, stability studies, and creation of appropriate storage requirements are all supported by the development of an appropriate stability-indicating method. The most popular combination of the RP-HPLC with a UV detector allows for the separation and quantification of contaminants [24]. The following are the steps involved in the development of SIM on HPLC which meets the regulatory requirements [25].

1.Sample generation:

The API is forced to deteriorate under conditions that are more severe than accelerated degradation settings in order to generate samples for SIM. It involves drug breakdown under the previously stated hydrolytic, oxidative, photolytic, and thermal conditions [26]. In order to produce degradation products that are likely to develop under actual storage conditions, forced degradation of API in solid state and solution form is conducted [27]. The development of a SIM then uses this sample. [28].

2.Method development and optimization:

The foundation for developing an HPLC method is laid by numerous physiochemical parameters of the drug, such as its pKa value, log P, solubility, and maximal rate of absorption. The selection of the mobile phase and sample solvent is aided by log P and solubility, while the mobile phase's pH is aided by the pKa value. [29]

As the degradation occurs in an aqueous solution, the reverse phase column is the ideal choice to begin the separation of sample components. For the first stages of separation, the mobile phase made up of acetonitrile, water, and methanol can be utilized in a variety of ratios. Based on the analyte's solubility, methanol or acetonitrile should be chosen for the organic phase. In order to achieve a decent separation of peaks, the water: organic phase ratio can initially be set at 50:50 and relevant adjustments can be made as trials advance. If the additional buffer is needed to improve peak symmetry and separation, it can be added mobile phase buffer should be compatible with MS if the approach is to be extended to liquid chromatography-mass spectrometry (LC-MS), such as trifluoroacetic acid and ammonium formate. The selectivity of the approach is impacted by column temperature variation since various analytes react differently to temperature fluctuations. To achieve good consistency, a temperature in the 30–40°C range is ideal [30]. The drug peak should be pushed further up the chromatogram since this separates all degradation products. In order to acquire the degradant peak eluting after the drug peak, a sufficient run time after the drug peak must be permitted. When developing a technique, it is possible that the drug peak conceals an impurity or degradation peak that co-elutes with the drug. Peak purity analysis, which establishes the method's specificity, is necessary for this. Online direct analysis employing photodiode array (PDA) detection is possible [31]. PDA offers data on the homogeneity of the spectral peak, but it does not apply to degradants whose UV spectra are comparable to those of drugs. The indirect technique entails altering the chromatographic parameters, such as the mobile phase ratio and column, which will impact peak separation. Then, the original spectra are contrasted with the spectrum of the altered chromatographic condition. It can be determined that a drug peak is homogenous if both the degradant peaks and the drug peak's area % remain constant. If it is discovered that the co-eluting degradant was not created under rapid and long-term storage circumstances, it would be acceptable. Then, by altering the flow rate, injection volume, column type, and mobile phase ratio the technique is made to work best for separating closely eluting peaks [32].

3.Method validation:

The created SIM is then validated in accordance with USP/ICH guidelines for method linearity, accuracy, precision, specificity, quantitation limit, detection limit, ruggedness, and robustness. [33]. The degradants discovered to be above the identification threshold (about 0.1%) must be isolated, identified, and quantitated. The technique is updated and revalidated if it does not meet the acceptance requirements for validation.

10. Analytical tools for degradant separation and identification:

A. Conventional Techniques:

1. Thin layer chromatography (TLC):

Preparative thin-layer chromatography (TLC) has been shown to be quite beneficial for many years. TLC has a low throughput in terms of the amount of material that can be retrieved for structure analysis while being quick, simple, and affordable. Usually, it is only used for MSproposed structures [34].

2. Solid phase extraction (SPE):

Prior to isolation, it is a quick approach to enrich and simplify a sample matrix. SPE is useful in the post-isolation process as a way to de-salt and remove large volumes of water from gathered semi-preparative chromatographic fractions due to how simple it is to use [35].

3. Accelerated solvent extraction (ASE):

It is a quick and efficient approach to quickly remove API and contaminants from a solid matrix using organic solvents. [48–50] Limitations included the possibility that the use of high temperatures and high pressures would cause the extracted chemicals to degrade. [36]

4. Low-pressure LC (LPLC):

When NMR analysis is required to support the identification of a degradant, flash chromatography (FC), one of the low-pressure chromatography methods, is the traditional method of choice. FC is a reasonably cheap method that can process milligram-to-gram volumes of material quickly, yet is adequate for separations that only need modest resolution.

5. Supercritical fluid extraction (SFE):

Both the pharmaceutical and natural product industries have found use for counter-current chromatography (CCC) and the use of carbon dioxide in structure elucidation procedures. Unusually suitable for unstable chemicals, CCC is a high-resolution chromatographic option without a solid stationary phase. [37]

6. Mass Spectrometry (MS):

Every workflow for structure elucidation requires the use of MS. Large sensitivity, large dynamic range, richness of information, and the ability to connect to LC separations directly and offer structural information "on the fly" are all features of this method. Over the past two decades, MS instrumentation has advanced significantly, increasing the availability of high-resolution instruments. A modern time-of-flight (TOF) device had a typical resolution of 10000-20000 about ten years ago. Multiple suppliers recently made TOF instruments often deliver resolution in the 40000–60000 range without losing sensitivity. [38] The gold standard for structural elucidation has been an ion trap instrument with multiple-stage fragmentation. The fragmentation experiment for the API is often conducted first, followed by the assignment of its pieces in order to comprehend the fragmentation of the molecule [39]. The impurity can then be subjected to the same fragmentation experiment, and fragments for both the API and the impurity can be compared. [40]

7. Nuclear Magnetic Resonance (NMR):

A very effective method for analyzing drug breakdown products is NMR spectroscopy [41,42,43]. The workflow for drug degradation products can benefit greatly from the integration of the rich structural data provided by NMR spectroscopy with a molecular formula and further structural understanding from MS fragmentation investigations. It is customary to isolate enough material (>1 mg) for NMR analysis in order to do NMR-based structural elucidation of drug-degradant products. The chemical structure can then be deduced by putting together correlated pieces of the molecule using one- and two-dimensional NMR measurements. These tests may now be run on isolated samples in the microgram range because of advancements in NMR-probe technology.

8. High-Performance Liquid Chromatography (HPLC):

Degradants are typically separated using HPLC. Nowadays, the typical UV HPLC detectors provide simultaneous measurements at many wavelengths, and some of them even produce ratio graphs at two different wavelengths. In the course of developing SIMs, this method has also been supported for peak purity testing [44]

B. Hyphenated Techniques

1. GC-MS

The first hyphenated method was GC-MS, and it is still essential for confirming the presence of residual solvents and organic volatile IMPs in samples [45-48]. However, for the majority of organic impurities and degradants, the characteristics of analytes necessary for GC-MS, such as volatility and thermal stability, are unknown beforehand. As a result, there are only infrequent literature reports on the use of this technology in the characterization of contaminants that are relevant to the pharmaceutical industry.

2. LC-MS

Of all the hyphenated methods for characterizing impurities, LC-MS, and its variations are the most often used since they have the ability to provide nearly conclusive structural data even on their own. The following is the range of advanced instruments with LC-MS. [49],

• LC-MS (Single Quad).

• LC-MS-MS (Triple Quad).

• LC-TOF.

• LC-MS-TOF (Q-TOF, Triple TOFTM) [55].

• LC-MS-3DTRAP (MSn).

• LC-MS-2DTRAP (Q-TrapTM).

• LC-Hybrid Trap TOF Systems (LCMS-IT-TOF®).

• LC-OrbitrapTM.

• LC-FTICR (Fourier Transform Ion Cyclotron Resonance) [50].

High-resolution mass spectrometry (HRMS), multistage mass spectrometry (MSn), and hydrogen/deuterium exchange mass spectrometry (HDE-MS) are three common LC-MS system functions that give major input towards elucidating the structure of degradation products.

3. Capillary Electrophoresis- Mass Spectrometry (CE-MS):

For the separation of impurities and degradation products, capillary electrophoresis (CE) and capillary electrochromatography (CEC) are significant orthogonal techniques [54]. CEC is a hybrid technology that combines LC's mobile and stationary phase selectivity with CE's high efficiency. Though still in the exploratory stage and limited to the development of separation techniques, the study of the utility of various CE modes, and judgment of the benefit of various types of mass spectrometers for the purpose, systems where CE and CEC are hyphenated with MS are gradually becoming more significant for the characterization of degradants. [56]

4. Liquid Chromatography- Nuclear Magnetic Resonance (LC-NMR):

The first report on the connection of LC effluent to NMR was made in 1978. [51] Since then, a number of instruments have been put in place in industrial and academic labs. Modern LCNMR systems are linked to a number of technological developments, including the use of cryoprobes, microprobes, and high-field magnets to enhance instrument sensitivity and resolution. Magnets with field strengths of 500 MHz and higher are frequently used as attachments to LC. varying inner diameters of the flow-through microprobes are available to accommodate the processing of varying sample quantities from LC. Since lowering the temperature boosts the reaction, cryogenic chilling facilitates the detection of sub-microgram amounts. [57]. The advantages of using NMR in combination with HPLC in comparison to HPLC-MS coupling are

(1) both HPLC and NMR are conducted in solution and no transfer from one phase to another is, as from the liquid to vapor phase in HPLC-MS;

(2) NMR measurements are not constrained by molecular weight or vaporization.;

(3) NMR spectra can often provide more comprehensive structure information, especially when the stereochemistry of the molecule is taken into account. [58]

5. Liquid chromatography-Fourier Transfer Infrared (LC-FTIR):

Since 1–5 mg of the sample is typically needed for IR spectra recording, it becomes challenging when components are present or created in tiny amounts and cannot be isolated [52]. This is what led to the development of LC-IR systems, which have just lately begun to be sold commercially. There aren't many studies in the literature that use LC-IR to characterize degradants. The effectiveness of the LC-FTIR system as a standalone method for impurity profiling was assessed by Somsen et al. [59]. A fresh sample of testosterone undecanoate and a stability sample that had been held at 60 C and 75% RH for five months each was examined using LC-FTIR in this study. The analysis of IR spectra and comparison with the drug spectrum revealed that the degradation product lacked the distinctive bands of conjugated C-3 carbonyl (1675 cm1) and nearby conjugated C=C (1610 cm1), indicating that the double bond in the steroid skeleton had been saturated. [60].

11. Conclusion:

Forced degradation studies serve to clarify the structure of the degradants and offer information on potential degradation pathways and products of the active components. Potential degradation products that may or may not arise under appropriate storage circumstances are produced by forced degradation experiments, but they aid in the development of stability-indicating methods. It is preferable to begin degradation research earlier in the medication development process so that there is enough time to gather more knowledge about the molecule's stability. With the use of this knowledge, the formulation manufacturing process may be improved, and storage conditions can be established. This study calls for the experimenter to utilize common sense because no one set of circumstances applies to all medicinal goods and drug substances, and the regulatory advice is vague regarding the conditions that should be applied. Any forced degradation strategy's goal is to achieve the specified level of deterioration, or 5-20%. An adequate sample for the development of a stability-indicating technique would be produced by a carefully planned and carried out forced degradation investigation.

References:

1. Sherawat R, Maithani M, Singh R, Regulatory aspects in development of stability indicating method: A Review. Chromatographia 2010; 72: 1-6.
2. G.T.Kulkarni, K.Gowthamarajan, B.Suresh, Indian Journal Of Pharmaceutical Education, 2004; 38(4), 194
3. G.T.Kulkarni, K.Gowthamarajan, B.Suresh, Indian Journal Of Pharmaceutical Education, 2004; 38(4), 194
4. B.E. Richter: The extraction of analytes from solid samples using accelerated solvent extraction. LCGC; 1999; 17:522–528.
5. S.Singh, Joural of Pharmaceutical and biomedical analysis, 2002, 28:1011-1040.
6. Suganya, S.; Bright, A.; Devi, T. S. R. Studies on Linearity and Assay Using RP-HPLC and UV–Visible Spectroscopy for the Drugs Oxcarbazepine and Pioglitazone Before and After Expiry Period. Int. J. Pharm. Sci. Res. 2012, 3(6), 1731–1734
7. H. Trabelsi, I.E. Hassen, S. Bouabdallah, et al., Stability indicating LC method for determination of Pipamperone, J. Pharm. Biomed. Anal. 39 (2005) 914–919.
8. Kumar, B. S. J.; Kumar, R. V.; Sinha, V. R. Stability Indicating HPTLC Method for the Determination of Pregabalin in Bulk and Pharmaceutical Dosage Forms. Sci. Pharm. 2013, 12(10), 376–383.
9. Chakravarthy, V. K.; Sankar, D. G. Stability Indicating HPLC Method for Determination of Lacosamide and Its Degradation/ impurities in Bulk and Pharmaceutical Formulation. Rasayan J. 2012, 5(3), 293–310
10. H. J. Leis, G. Fauler, and W. Windischhofer, "Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry," Journal of Mass Spectrometry, vol. 37, no. 5, pp. 477–480, 2002.
11. B.E. Richter: The extraction of analytes from solid samples using accelerated solvent extraction. LCGC; 1999; 17:522–528.
12. M.A. Mottaleb, S.D. Sarker: Accelarated solvent extraction for natural products isolation. in: S.D. Sarker, L. Nahar (Eds.), Methods in Molecular Biology, Humana Press, New York, edition 3, 2012, 75–87.
13. R. Hu and Y. Pan: Recent trends in counter-current chromatography. Trends in Analytical Chemistry 2012; 40:15–27.
14. A. Blanchard, C. Lee, B. Nickerson, L. Lohr, A. Jensen, K.M. Alsante, T.R. Sharp, D.P. Santafianos, R. Morris and K.D. Snyder: Identification of low-level degradants in low dose tablets. Journal of Pharmaceutical and Biomedical Analysis; 2004; 36:265–275
15. Mullani, A., (2021). FORCED DEGRADATION STUDY – A NEW APPROACH FOR STRESS TESTING OF DRUG SUBSTANCES AND DRUG PRODUCTS; INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH; 12(5). 2683-91
16. Ueyama, E., Takahashi, F., Ohashi, J., Konse, T., Kishi, N., & Kano, K. (2012). Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions. *Journal of pharmaceutical and biomedical analysis*, *61*, 277–283.
17. K.C. Waterman, R.C. Adami, K.M. Alsante, J. Hong, M.S. Landis, F. Lombardo, C.J. Roberts, Stabilization of pharmaceuticals to oxidative degradation, Pharmaceutical Development and Technology 7 (1) (2002) 1–32.
18. Ravisankar, P., Swathi, V., Babu, P.S., Md., Sulthana, S., & Gousepeer, S. (2017). Current Trends in Performance of Forced Degradation Studies and Stability Indicating Studies of Drugs; IOSR Journal of Pharmacy and Biological Sciences; Volume 12, Issue 6 Ver. II (Nov. – Dec. 2017), PP 17-36
19. Singh, R., (2012). Current trends in forced degradation study for pharmaceutical product development; Journal Pharmacy Education Research; Vol. 3, Issue No. 1, June 2012, 53-63.
20. D.W. Reynolds, Forced degradation of pharmaceuticals, American Pharmaceutical Review 7 (3) (2004) 56–61
21. FDA, INDs for Phase II and III Studies of Drugs, Including specified Therapeutic Biotechnology derived products, Federal Register (Notices) 64(76): 19543-19544.
22. ICH, Good Manufacturing Practices for Active Pharmaceutical Ingredients. International Conference on Harmonisation, IFPMA, Geneva, 2000, p. 35
23. Ranasinghe, R. Ramanathan, J. Ragu, D. Mohammed, J. Celia, W.G. Humphreys and T.V. Olah: Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS. BioAnalysis; 2012; 4:511–528.

24. FDA Guidance for Industry, Analytical procedures and Methods Validation: Chemistry, manufacturing and Controls Documentation, Draft Guidance, Food and Drug Administration.

25. Karen M. A., The role of degradant profiling in active pharmaceutical ingredients and drug products; Advanced Drug Delivery Reviews; 59 (2007) 29–37

26. FDA, Guidance for Industry: Analytical Procedures and Methods Validation (Draft guidance). Food and Drug Administration, Rockville, MD, 2000

27. L.R. Synder, J.L. Glajch, J.J Kirkland, Practical HPLC Method Development, second ed., Wiley, New York, 1997

28. Patel, A.; Suhagia, B. N.; Patwari, A. Stability Indicating Assay Method for Quantification of Lacosamide in Bulk and its Pharmaceutical Dosage Form and Characterization of Major Degradation Products. Int. J. Pharm. Pharm. Sci. 2013, 6(1), 593–599

29. M. Grover, M. Gulati and S. Singh: Journal of Chromatography B: Biomedical Sciences and Application; 1998; 708:153–159.

30. M.P. Riddhiben, M.P. Piyushbhai, M.P. Natubhai, Stability indicating HPLC method development—a review, Int. Res. J. Pharm. 2 (5) (2011) 79–87.

31. Rao, N; A REVIEW ON DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHODS FOR ANALYSIS OF ACIDIC DRUGS; International Journal of Current Pharmaceutical Research; Vol 11, Issue 4, 2019, 22-33.

32. Thammana M. A review on high-performance liquid chromatography (HPLC). Res Rev: J Pharm Anal 2016;5:22-8

33. Malviya R, Bansal V, Pal OP, Sharma PK. High-performance liquid chromatography: a short review. JGPT 2010;2:22-6.

34. M. Allwood, J. Plane, The wavelength-dependent degradation of vitamin A exposed to ultraviolet radiation, Int. J. Pharm. 31 (1986) 1–7

35. R.H. Muller, W. Mehnert (Eds.), Particle and Surface Characterization Methods. Medpharm Scientific Publishers, Stuttgart, pp. 129–157

36. K.M. Alsante, T.D. Hatajik, D. Santafianos, T.S. Sharp, L.L. Lohr, Impurity isolation and characterization case studies, in: S. Ahuja, K.M. Alsante (Eds.), Handbook of Isolation and Characterization of Impurities in Pharmaceuticals, Academic Press (Elsevier), New York, 2003, pp. 361-400

37. S.J. Byrn, R.R. Pfeiffer, J.G. Stowell, Theoretical analysis of solid-state chemical reactions, in: S.J. Byrn, R.R. Pfeiffer, J.G. Stowell (Eds.), Solid State Chemistry of Drugs, Second edition, SSCI, Inc., West Lafayette, Indiana, 1999, 307.

38. D.W. Reynolds, K.L. Facchine, J.F. Mullaney, K.M. Alsante, T.D. Hatajik, M.G. Motto, Available guidance and best practices for conducting forced degradation studies, Pharmaceutical Technology 26 (2) (2002) 48–54.

39. Uma, G.; Manimala, M.; Vasudevan, M.; Karpagam, S.; Deecarman. LC–MS–MS Method for the Determination of Pregabalin in Human Plasma. Int. J. Pharm. Pharm. Sci. 2012, 4(3), 2–6.

40. M.A. Nussbaum, P.J. Jansen, S.W. Baertschi, Role of "Mass Balance" in pharmaceutical stress testing, in: S.W. Baertschi (Ed.), Pharmaceutical Stress testing: Understanding Drug Degradation, Taylor and Francis Group, New York, 2005, pp. 181–204.

41. M. Elyashberg, A. Williams and G. Martin: Computer – assisted structure verification and elucidation tools in NMR-based structural elucidation. Progress in Nuclear Magnetic Resonance Spectroscopy 2008 53:1–104

42. M. Malet-Martino and U. Holzgrabe: NMR techniques in biomedical and pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis; 2011; 55:1–15.

43. Cheekatla S, Ravichandrababu R, and Reddy BN: Determination and characterization of degradation products of Anastrozole by LC–MS/MS and NMR spectroscopy. Journal of Pharmaceutical and Biomedical Analysis; 2011; 56: 962-968.

44. Malviya R, Bansal V, Pal OP, Sharma PK. High-performance liquid chromatography: a short review. JGPT 2010;2:22-6.

45. N.L. Bochkareva, I.N. Glazkov and I.A. Revelsky: Combination of supercritical fluid extraction and gas chromatography-mass spectrometry: determination of impurities extracted from tablet preparations of the benzodiazepine series. Journal of Analytical Chemistry; 2006; 61:1082–1089.

46. D. Djozan, A. Jouyban and J. Norouzi: Ultrasonic assisted SPME coupled with GC and GC-MS using pencil lead as a fiber for monitoring the organic volatile impurities of ceftazidime, Journal of Chromatographic Sciences; 2008; 46:680–685.

47. K. Fliszar, J.M. Wiggins, C.M. Pignoli, G.P. Martin and Z. Li: Analysis of organic volatile impurities in pharmaceutical excipients by static headspace capillary gas chromatography. Journal of Chromatography A; 2004; 1027:83–91.

48. G.L. McClure: Improved determination of organic volatile impurities in pharmaceutical materials by (USP-467) using automated static headspace GC/MS, PDA. Journal of Pharmaceutical Sciences and Technology; 1999; 53:129–136.

49. H. Trabelsi, I.E. Hassen, S. Bouabdallah, et al., Stability indicating LC method for determination of Pipamperone, J. Pharm. Biomed. Anal. 39 (2005) 914–919

50. J.W. Dolan, Stability-indicating assays: LC troubleshooting, LC-GC N. Am. 20 (4) (2002) 346–349.

51. Ernst Bayer, Klaus Albert, Michael Nieder and Edgar Grom: On-line coupling of high-performance liquid chromatography and nuclear magnetic resonance. Journal of Chromatography; 1979; 86:497-507.

52. G.W. Somsen, C. Gooijer, U.A.T. Brinkman, N.H. Velthorst and T. Visser: Coupling of LC and FT-IR: impurity profiling of testosterone undecanoate. Applied Spectroscopy; 1992; 46:1514–1519.

53. K.M. Alsante, K.D. Snyder, M. Swartz, C. Parks, Applications development using out-of-the-box software: a structure searchable degradation/ impurity database, Scientific Computing and Instrumentation (June 2002) 30–37

54. Shihabi, Z. K.; Oles, K.; Hinsdale, M. Analysis of the Antiepileptic Drug Keppra by Capillary Electrophoresis. J. Chromatogr. A 2003, 1004, 9–12.

55. Rodr, J.; Casta, G.; Mu, L. Direct Determination of Pregabalin in Human Urine by Nonaqueous CE-TOF-MS. Electrophoresis 2013, 34, 1429–1436.

56. Naidu, Y. K.; Reddy, R. S.; Divi, K. R.; Reddy, M. P. K.; Chandiran, I. S.; Jayaveera, K. N. Quantification of Levetiracetam in Human Plasma with Precipitation Extraction by Using Fully Validated LC-MS / MS and its Application to a Bioequivalence Study. Res. J. Pharm. Technol. 2010, 3(3), 847–852.

57. George M. Hanna., A Stability Indicating Proton NMR Spectroscopic Assay Method for Succinylcholine Chloride Injections., analytical biochemistry and clinical analysis, 2006, 18(17),2183-2194

58. Modini, A.K., Ranga, M., Identification, Isolation, and Structural Characterization of Novel Forced Degradation Products of Darunavir Using Advanced Analytical Techniques Like UPLC–MS, Prep-HPLC, HRMS, NMR, and FT-IR Spectroscopy. Chromatographia, 2023, 86, 63–78.

59. Somsen, G. W.; Rozendom, E. J. E.; Gooijer, C.; Velthorst, N. H.; Brinkman, U. A. T. Polymer Analysis by Column Liquid Chromatography Coupled Semi-on-Line with Fourier Transform Infrared Spectrometry. Analyst 1996, 121 (8), 1069–1074. https://doi.org/10.1039/AN9962101069 .

60. Celina, M.; Ottesen, D. K.; Gillen, K. T.; Clough, R. L. FTIR Emission Spectroscopy Applied to Polymer Degradation. *Polym. Degrad. Stab*. 1997, *58* (1), 15–31. https://doi.org/10.1016/S0141-3910(96)00218-2